Xilio Therapeutics Analyst Ratings
Xilio Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/21/2022 | 255.33% | Chardan Capital | → $7 | Initiates Coverage On | → Buy |
| 11/10/2022 | 559.9% | Raymond James | $31 → $13 | Maintains | Outperform |
| 08/10/2022 | 915.23% | Morgan Stanley | $32 → $20 | Maintains | Overweight |
| 01/10/2022 | 1727.41% | HC Wainwright & Co. | → $36 | Initiates Coverage On | → Buy |
| 11/16/2021 | 1473.6% | Raymond James | → $31 | Initiates Coverage On | → Outperform |
| 11/16/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 11/16/2021 | 1524.37% | Morgan Stanley | → $32 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 12/21/2022 | 255.33% | 查爾丹資本 | → $7 | 開始承保 | →購買 |
| 11/10/2022 | 559.9% | 雷蒙德·詹姆斯 | $31 → $13 | 維護 | 跑贏大盤 |
| 08/10/2022 | 915.23% | 摩根士丹利 | $32 → $20 | 維護 | 超重 |
| 01/10/2022 | 1727.41% | HC Wainwright公司 | → $36 | 開始承保 | →購買 |
| 11/16/2021 | 1473.6% | 雷蒙德·詹姆斯 | → $31 | 開始承保 | →跑贏大盤 |
| 11/16/2021 | — | 考恩公司 | 開始承保 | →跑贏大盤 | |
| 11/16/2021 | 1524.37% | 摩根士丹利 | → $32 | 開始承保 | →超重 |
What is the target price for Xilio Therapeutics (XLO)?
希利奧治療公司(XLO)的目標價格是多少？
The latest price target for Xilio Therapeutics (NASDAQ: XLO) was reported by Chardan Capital on December 21, 2022. The analyst firm set a price target for $7.00 expecting XLO to rise to within 12 months (a possible 255.33% upside). 4 analyst firms have reported ratings in the last year.
查爾丹資本於2022年12月21日報道了西裡奧治療公司(納斯達克：XLO)的最新目標價。這家分析公司將目標價定為7美元，預計XLO將在12個月內升至(可能上漲255.33%)。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for Xilio Therapeutics (XLO)?
希利奧治療公司(XLO)的最新分析師評級是多少？
The latest analyst rating for Xilio Therapeutics (NASDAQ: XLO) was provided by Chardan Capital, and Xilio Therapeutics initiated their buy rating.
納斯達克(Sequoia Capital：XLO)的最新分析師評級是由查爾丹資本提供的，希利奧治療公司啟動了買入評級。
When is the next analyst rating going to be posted or updated for Xilio Therapeutics (XLO)?
Xilio治療公司(XLO)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Xilio Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Xilio Therapeutics was filed on December 21, 2022 so you should expect the next rating to be made available sometime around December 21, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與希利奧治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Xilio治療公司的上一次評級是在2022年12月21日提交的，所以你應該預計下一次評級將在2023年12月21日左右提供。
Is the Analyst Rating Xilio Therapeutics (XLO) correct?
分析師對Xilio Treeutics(XLO)的評級正確嗎？
While ratings are subjective and will change, the latest Xilio Therapeutics (XLO) rating was a initiated with a price target of $0.00 to $7.00. The current price Xilio Therapeutics (XLO) is trading at is $1.97, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Xilio治療公司(XLO)評級是以0.00美元至7.00美元的目標價啟動的。希利奧治療公司(XLO)目前的交易價格為1.97美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。